June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Doxycycline Use and Risk of Post-operative Complications Following Keratorefractive Surgery
Author Affiliations & Notes
  • Braedon Murdock
    Ophthalmology, The George Washington University, Washington, District of Columbia, United States
  • Veronica Mark
    Ophthalmology, The George Washington University, Washington, District of Columbia, United States
  • Haig Pakhchanian
    Ophthalmology, The George Washington University, Washington, District of Columbia, United States
  • Rahul Raiker
    West Virginia University Health Sciences Center, Morgantown, West Virginia, United States
  • Neha Raparla
    Ophthalmology, The George Washington University, Washington, District of Columbia, United States
  • David Belyea
    Ophthalmology, The George Washington University, Washington, District of Columbia, United States
  • Footnotes
    Commercial Relationships   Braedon Murdock None; Veronica Mark None; Haig Pakhchanian None; Rahul Raiker None; Neha Raparla None; David Belyea None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4371 – A0308. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Braedon Murdock, Veronica Mark, Haig Pakhchanian, Rahul Raiker, Neha Raparla, David Belyea; Doxycycline Use and Risk of Post-operative Complications Following Keratorefractive Surgery. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4371 – A0308.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Doxycycline is a known treatment for meibomian gland disease (MGD), which is a major risk factor for the development of dry eye syndrome (DES) and recurrent corneal erosion (RCE). The degree to which pre-existing corneal conditions pose a risk for complications after keratorefractive surgery (KRS) is as yet undetermined. This study compared differences in outcomes in the 1-year postoperative period following KRS between patients with and without a 1-year history of doxycycline use.

Methods : A retrospective cohort study was conducted using TriNetX, a real-time, national, federated research network. Patients who underwent KRS were identified by Current Procedural Terminology (CPT) code and stratified into two cohorts based on their history of doxycycline use. Each subject was then matched to a control via 1:1 propensity score matching based on age, gender, BMI, and medical comorbidities such as essential hypertension, diabetes mellitus, and chronic lower respiratory diseases. The primary endpoint of the study was the comparative 1-year postoperative incidence of the following outcomes: DES, RCE, secondary corneal edema, corneal scar or opacity, corneal ectasia, acute conjunctivitis, diffuse lamellar keratitis, corneal neovascularization, vitreous degeneration, ischemic optic neuropathy, vitreous hemorrhage, retinal detachment or break, retinal edema, and cystoid macular degeneration.

Results : A total of 2,056 patients were included in the analysis with 1,028 patients in each cohort after propensity matching. The doxycycline cohort had a statistically significant higher risk of developing DES (RR 1.46, 95% CI 1.2-1.78; RD 6.32%, 95% CI 3.1-9.55) and RCE (RR 2.8, 95% CI 1.37-5.73; RD 1.75%, 95% CI 0.59-2.91) within 1 year of undergoing KRS compared to matched controls. No significant differences were detected between the two cohorts for the other 1-year postoperative outcomes.

Conclusions : Dry eye syndrome and RCE are commonly seen in the postoperative period of KRS and can impact the quality of life in patients. In this study, patients with a history of doxycycline use were significantly more likely to develop DES and RCE following KRS. All other assessed clinical outcomes revealed no significant difference. The severity of pre-existing corneal conditions should be considered when evaluating patients for KRS and discussing outcomes with patients both pre- and post-operatively.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×